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SelectDrug RehabFew medications are as infamous as thalidomide: in the late
1950’s the drug, prescribed to pregnant women as a mild
sedative and morning sickness remedy, caused severe
congenital malformations in tens of thousands of newborns.
The case had significant ramifications for the drug industry,
with agencies around the world, including the U.S. Food
and Drug Administration, restructuring their rules for drug
use and approval. In the ensuing years, the name thalidomide
became synonymous with medical disaster and the need for
safeguards in drug development. Yet, unexpectedly and
without much fanfare, thalidomide is getting a second
chance, proving its usefulness in treating diseases as dispa-
rate as cancer and leprosy. Indeed, due to its immunomodu-
latory and antiproliferative properties, thalidomide hasquietly
become an important treatment option for multiplemyeloma.DDB1-CRBN in complex with thalidomide. Inset highlights the com-
pound binding pocket (courtesy of Eric Fisher).
A molecular model of thalidomide.As thalidomide and its derivatives make their way back
into hospitals, research follows, seeking to uncover the
mechanisms of its seemingly incongruent physiological ef-
fects. Two new studies from the laboratories of Nicolas
Thoma¨ and Philip Chamberlain (Chamberlain et al., 2014;
Fischer et al., 2014) describe the structure of thalidomide
and its derivatives bound to a previously identified target,
the ubiquitously expressed protein cereblon that is part of
the cullin-4-containing E3 ubiquitin ligase complex CUL4–
RBX1–DDB1. These papers follow on the heels of three
studies published earlier this year by Benjamin Ebert,
William Kaelin, and Rajesh Chopra (Kro¨nke et al., 2014; Lu
et al., 2014, Gandhi et al., 2014), showing that the antiproli-
ferative effect of thalidomide on multiple myeloma arises
from its ability to activate cereblon’s E3-ligase activity, re-
sulting in the ubiquitination and degradation of the transcrip-
tion factors Ikaros (IKZF1) and Aiolos (IKZF3). This selective
targeting results in the dysregulation of B and T cell develop-
ment, underlying thalidomide’s ability to affect the immune
system.
Using structural approaches, Thoma¨ and Chamberlain
provide furthermolecular insights into this interaction. In their
study, Chamberlain and colleagues describe how thalido-
mide derivatives bind to cereblon and the CUL4–RBX1–
DDB1 complex, identifying key features of the structure
and the residues critical for the antiproliferative action of
the drugs. The Thoma¨ lab analyzed the structure of the
complex aiming to dissect the effects of thalidomide on
cereblon’s E3 ligase activity. They find that thalidomidebinding to cereblon and the subsequent degradation of
Ikaros interferes with the recruitment and regulation of a
previously unknown endogenous substrate, the transcription
factor MEIS2, which then becomes upregulated. Thus,
thalidomide influences two distinct cellular pathways,
inducing both loss- and gain-of-function changes that may
account for its pleiotropic effects.
These and other advances have brought renewed inter-
est in this controversial drug, which, if not fully rehabili-
tated, provides clear benefits to targeted patient popula-
tions. The insights into its mode of action lift a curtain on
a previously inscrutable compound and provide much
needed understanding of it effects, supporting the devel-
opment of new and safer derivatives. Indeed, the example
of thalidomide shows that examining the biology of drugs
that were disfavored for various reasons is valuable for
both fundamental and clinical advances.REFERENCES AND RECENT RELATED PAPERS
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